Loading stock data…
Ligand Pharmaceuticals Incorporated (LGND)
$314.04+10.45 (+3.44%)
Market ClosedLast close Jun 29
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Ligand Pharmaceuticals Incorporated in the Healthcare sector is trading at $314.04 with a market capitalization of $5.1B. Wall Street consensus targets $277.60 (10 analysts), implying a -11.6% move over the next 12 months. The stock is currently near its 52-week high of $314.80, remaining 53.1% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply -11.6% downside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $51.72M↓ | $59.67M↓ | $115.46M↑ | $47.63M↑ | $45.33M |
| Gross Profit | $48.45M↓ | $56.67M↓ | $111.66M↑ | $44.72M↑ | $40.48M |
| Operating Income | $17.37M↓ | $20.04M↓ | $54.10M↑ | $9.72M↑ | -$36.66M |
| Net Income | -$13.35M↓ | $44.78M↓ | $117.27M↑ | $4.85M↑ | -$42.45M |
Peer Comparison
JNJUNHPFE
Fundamentals
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA an...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$5.09B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
15.40%
Volume
Today's trading volume
459,556
Recent News
Stocks Mostly Lower on Weakness in Megacap Tech and Software Stocks
The S&P 500 Index ($SPX ) (SPY ) on Monday closed down -0.37%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.29%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.19%. September E-mini S&P futures (ESU26 ) fell -0.34%, and September E-mini Nasdaq futures...
Stocks Supported by Strength in Chipmakers and AI-Infrastructure Stocks
The S&P 500 Index ($SPX ) (SPY ) today is up +0.21%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.54%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.50%. September E-mini S&P futures (ESU26 ) are up +0.20%, and September E-mini Nasdaq futures...
Ligand Pharmaceuticals Director Unloads 2,501 Shares — Should You Be Concerned?
This biotech innovator, known for its royalty-driven model, reported a notable insider sale amid a period of strong share price gains.
A Ligand Pharmaceuticals (LGND) Insider Sold 5,000 Shares for $1.1 Million
Biotech royalty player Ligand Pharmaceuticals reported a notable insider sale following a year of strong stock performance.
How The Ligand Pharmaceuticals (LGND) Investment Story Is Evolving Without Fresh Analyst Targets
Ligand Pharmaceuticals enters this update cycle with no change in its existing price targets, which can matter for how you frame expectations around the stock. Even without new price target moves or fresh analyst commentary, the current setup still offers useful signals about how the story is holding together. In the sections that follow, you will see how to read these signals and keep up with the evolving analyst narrative around Ligand. Stay updated as the Fair Value for Ligand...